Yu Cong, Saurabh Dixit, Donna L Perry, Louis M Huzella, Erin Kollins, Russell Byrum, Scott M Anthony, David Drawbaugh, Sanae Lembirik, Elena Postnikova, Brett Eaton, Michael Murphy, Gregory Kocher, Kyra Hadley, Anthony E Marketon, Rebecca M Bernbaum, Amanda M W Hischak, Randy Hart, Nick Vaughan, Jiro Wada, Jing Qin, Marisa C St Claire, Connie S Schmaljohn, Michael R Holbrook
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and onset of the coronavirus disease-19 (COVID-19) pandemic led to an immediate need for therapeutic treatment options. Therapeutic antibodies were developed to fill a gap when traditional antivirals were not available. In late 2020, the United States Government undertook an effort to compare candidate therapeutic antibodies in virus neutralization assays and in the hamster model of SARS-CoV-2 infection. With the emergence of SARS-CoV-2 variants, the effort expanded to evaluate the efficacy of nearly 50 products against major variants...
August 13, 2024: Antiviral Research